Trang Nguyen-Le, DO
Nephrology · Henderson, NVNPI 1043471758
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Vifor Pharma, Inc. at 33.7% of the total.
Across 276 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$2K
- AstraZeneca$824
- Otsuka America Pharmaceutical, Inc.$700
- Bayer$421
- Amgen$311
- Mallinckrodt Hospital Products Inc.$235
- plus $523 from 14 others
What the payments were for
- Food & beverage$4,46698%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 118 | $1,531 |
| AstraZeneca(2 entities) | 40 | $824 |
| Otsuka America Pharmaceutical, Inc. | 40 | $700 |
| Bayer | 24 | $421 |
| Amgen(2 entities) | 17 | $311 |
| Mallinckrodt Hospital Products Inc. | 10 | $235 |
| ANI Pharmaceuticals, Inc. | 6 | $142 |
| OPKO Pharmaceuticals, LLC | 3 | $53 |
| Fresenius USA Marketing, Inc. | 3 | $43 |
| Akebia Therapeutics Inc | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Ardelyx, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Calliditas Therapeutics US Inc. | 1 | $27 |
| Merck | 1 | $27 |
| Novo Nordisk | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| GSK | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $12 |
How this compares
$4,545 in reported general payments places this provider in the 75th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DapagliflozinDapagliflozin Propanediol | 22 | $20,516 |
| FarxigaDapagliflozin Propanediol | 15 | $15,895 |
| JardianceEmpagliflozin | 14 | $12,796 |
| Calcitriol | 75 | $1,712 |
| Torsemide | 22 | $564 |
| Hydralazine Hcl | 23 | $357 |
| Potassium Chloride | 23 | $331 |
| Allopurinol | 26 | $234 |
| Nifedipine ErNifedipine | 23 | $216 |
| Furosemide | 42 | $202 |
| Amlodipine Besylate | 32 | $180 |
| Tamsulosin Hcl | 17 | $167 |
| Losartan Potassium | 16 | $162 |
| Lisinopril | 16 | $156 |
| Metoprolol Succinate | 18 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $824 | $15,89515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 125 nephrology providers in Nevada.
Other nephrology in Henderson
- Sundar SankaranHenderson$13K
- Dijana JeficHenderson$5K
- Basker PeriyasamyHenderson$4K
- Moiz DawoodHenderson$4K
- Qin FangHenderson$2K
- Samuel KantorLas Vegas$319K
- Richard CottieroLas Vegas$220K
- Mark VishnepolskyLas Vegas$68K
- Jusmin PatelReno$43K
- Mukesh SharmaReno$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.